Sangamo BioSciences (SGMO) Announced Key Milestone Reached in Cell Engineering Agreement With Genentech
More News related to SGMO
- Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
- Sangamo (SGMO) Reports Q3 Loss of $0.12, Beats by 1c
- Sangamo BioSciences Reports Third Quarter 2009 Financial Results
- Sangamo BioSciences Announces Presentation at Merriman Curhan Ford's Investor Summit 2009
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
More News related to FDA
- Endo Pharmaceuticals (ENDP) Receives Complete Response Letter From FDA Regarding AVEED
- Simcere Pharma (SCR) Rabies Vaccine to be Investigated by China's SFDA
- Cubist Pharmaceuticals (CBST) Temporarily Suspends Enrollment In One Trial After More Deaths
- AstraZeneca (AZN) and Targacept (TRGT) To Collaborate to Develop and Commercialize TC-5214 MDD Drug
- Cephalon (CEPH) Files Patent Infringement Lawsuit Against Teva (TEVA)
Sangamo BioSciences, Inc. (Nasdaq: SGMO) said a key research milestone has been achieved in its Research and License Agreement with Genentech, Inc., a wholly-owned member of the Roche Group, for the generation of cell lines with novel characteristics for pharmaceutical protein production purposes using Sangamo's proprietary zinc finger DNA-binding protein nuclease (ZFN) technology.
Genentech scientists demonstrated the successful knockout of two preselected genes in a Chinese hamster ovary (CHO) cell line.
The milestone achievement triggered a payment from Genentech to Sangamo
Related Categories
FDAMomentum Movers
Stocks Mentioned
+0.00Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
sucessful ZFN knockpout of 2 CHO genes
Barry on Jul 2, 2009 06:21 PMSo are we to assume that Genentech is targeting OVARIAN CANCER? They succesfully knocked out those genes to stop the cancer?